Syndax Pharmaceuticals, Inc..
SNDX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Syndax Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of cancer. The company's pipeline includes clinical-stage product candidates such as revumenib, an oral menin inhibitor being developed for the treatment of acu...Show More
Better Health for All
-40
Syndax Pharmaceuticals is a biopharmaceutical company focused on developing innovative cancer therapies, with two FDA-approved products, Revuforj and Niktimvo, for acute leukemias, AML, and chronic graft-versus-host disease.
1
The company's entire business is devoted to health improvement, with Revuforj demonstrating significant efficacy in clinical trials, including an 86% overall response rate and 76% complete remission in some patient groups.
2
The company's products are not considered to have significant negative health impacts, as they are designed to treat life-threatening conditions. However, Revuforj carries substantial safety risks, with 76% of patients experiencing serious adverse reactions and 4% experiencing fatal adverse reactions in clinical trials (9 out of 241 patients).
3
Differentiation Syndrome occurred in 25% of patients (12% Grade 3/4, 2 fatal), and QTc prolongation in 36% (15% Grade 3, 2% Grade 4, 1 fatal cardiac arrest).
4
The company provides comprehensive safety information, including boxed warnings, and offers patient support programs like SyndAccess, which includes financial assistance for eligible U.S. patients.
5
A Managed Access Program is also in place to expand access to Revuforj in regions outside the U.S. where it is not commercially available, covering over 150 countries.
6
Revuforj is approved for adult and pediatric patients one year and older, and Niktimvo for pediatric patients weighing at least 40 kg.
7
Syndax expects to invest approximately $400 million in research and development plus selling, general, and administrative expenses for 2026, with ongoing clinical trials to expand product use.
8
The company ensures that its managed access and clinical trial programs adhere to local regulatory and ethical frameworks, and SyndAccess nurses provide one-on-one support to patients.
9
Fair Money & Economic Opportunity
0
Syndax Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing cancer therapies.
1
The company's core business does not involve lending, insuring, moving, or storing money for consumers, nor does it offer deposit services or consumer credit products.
2
Therefore, all KPIs related to fair money and economic opportunity, which are designed for financial institutions, are not applicable to Syndax Pharmaceuticals, Inc. The company's patient support programs and copay assistance relate to the cost of its pharmaceutical products, not financial services as defined by the rubric.
3
Fair Pay & Worker Respect
50
For fiscal year 2024, Syndax Pharmaceuticals' CEO-to-median employee pay ratio was 22:1.
1
Employee engagement is reflected in a 4.8 out of 5-star rating based on 87 anonymous reviews.
2
Additionally, 96% of employees would recommend working at the company, and 100% approve of the CEO.
3
The company was also named one of Glassdoor's Best Places to Work in 2025, ranking
4
.
5
Fair Trade & Ethical Sourcing
0
No specific data points or facts related to SNDX.US's fair trade and ethical sourcing practices, supplier audits, labour incidents, supply chain traceability, remediation speed, ethical clauses in contracts, materials risk, or supplier diversity spend were found in the provided articles.
1
Honest & Fair Business
0
No evidence available to assess Syndax Pharmaceuticals, Inc. on Honest & Fair Business.
Kind to Animals
0
No specific data or metrics regarding Syndax Pharmaceuticals, Inc.'s (SNDX.US) performance on animal welfare, animal testing, or related practices were found in the provided articles.
1
One article explicitly stated that no direct data was available for SNDX.US.
2
The other article focused on FDA policies and plans, not the company's actions or specific metrics.
3
No War, No Weapons
0
No evidence available to assess Syndax Pharmaceuticals, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess Syndax Pharmaceuticals, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No evidence available to assess Syndax Pharmaceuticals, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
The provided articles do not contain specific, quantifiable evidence for any of the Safe & Smart Tech KPIs for Syndax Pharmaceuticals, Inc. While general cybersecurity practices such as vulnerability identification, assessment processes, penetration testing, and data encryption are mentioned, no concrete details, percentages, frequencies, or outcomes are provided to allow for scoring against the rubric's quantitative thresholds.
1
There is no information regarding data breaches specific to the company, AI ethics, cybersecurity investment, privacy certifications, security training, algorithmic transparency, unauthorized data use, user data control, authentication security, bug bounty programs, privacy by design, data minimization, regulatory compliance, algorithmic harm remediation, or digital rights advocacy.
2
Zero Waste & Sustainable Products
0
No evidence available to assess Syndax Pharmaceuticals, Inc. on Zero Waste & Sustainable Products.